IP Library Granted Patent US 8,754,109
Granted Patent B2
US 8,754,109 · App. 13/513,472 · Granted Jun 17, 2014

Pirfenidone therapy and inducers of cytochrome P450

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,754,109
App. No.
13/513,472
Granted
Jun 17, 2014
Kind
B2
Abstract

The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.

Claims (19)

1. A method of increasing the effectiveness of pirfenidone therapy by avoiding decreased exposure to pirfenidone, in a patient in need of pirfenidone therapy and taking a strong inducer of cytochrome P450 1A2 (CYP1A2), comprising administering to the patient a therapeutically effective amount of pirfenidone, and avoiding the strong inducer of a cytochrome P450 1A2 (CYP1A2).

2. The method of claim 1 , wherein the patient has idiopathic pulmonary fibrosis.

3. The method of claim 1 , wherein the patient suffers from a fibrosis condition.

4. The method of claim 1 , wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg.

5. The method of claim 2 , wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg.

6. The method of claim 1 , wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg.

7. The method of claim 2 , wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg.

8. The method of claim 1 , wherein each dose of pirfenidone administered is 801 mg.

9. The method of claim 6 , wherein pirfenidone is administered three times a day.

10. The method of claim 9 , wherein pirfenidone is administered with food.

11. The method of claim 1 , wherein the strong CYP1A2 inducer is cigarette smoke.

12. The method of claim 11 , wherein the patient has idiopathic pulmonary fibrosis.

13. The method of claim 11 , wherein the patient suffers from a fibrosis condition.

14. The method of claim 11 , wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg.

15. The method of claim 12 , wherein the pirfenidone is administered at a total daily dosage of at least 1800 mg.

16. The method of claim 11 , wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg.

17. The method of claim 12 , wherein the pirfenidone is administered at a total daily dosage of 2400 mg or 2403 mg.

18. The method of claim 16 , wherein pirfenidone is administered three times a day.

19. The method of claim 18 , wherein pirfenidone is administered with food.

Assignments (4)
SECURITY INTEREST Recorded Mar 23, 2026
From: LEGACY PHARMA INC. SEZC
To: ROOSTER LP
Reel/Frame 074151/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2025
From: INTERMUNE, INC.
To: LEGACY PHARMA INC. SEZC
Reel/Frame 070877/0547 →
CERTIFICATE OF CHANGE OF COMPANY'S ADDRESS Recorded Jul 27, 2018
From: INTERMUNE, INC.
To: INTERMUNE, INC.
Reel/Frame 046638/0466 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2013
From: BRADFORD, WILLIAMSON ZIEGLER; SZWARCBERG, JAVIER
To: INTERMUNE, INC.
Reel/Frame 031233/0665 →